(3.237.234.213) 您好!臺灣時間:2021/03/09 13:01
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:許永佳
研究生(外文):Yung-Chia Hsu
論文名稱:抗結核藥物致肝毒性與病人疾病相關之研究
論文名稱(外文):Correlation between Antituberculosis Drug-Induced Hepatotoxicity and Patient’s Diseases
指導教授:溫燕霞溫燕霞引用關係
指導教授(外文):Yen-Hsia Wen
學位類別:碩士
校院名稱:高雄醫學大學
系所名稱:藥學研究所碩士在職專班
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2010
畢業學年度:99
語文別:中文
論文頁數:85
中文關鍵詞:肝毒性抗結核藥物共病
外文關鍵詞:hepatotoxicityantituberculosis drugcomorbidity
相關次數:
  • 被引用被引用:1
  • 點閱點閱:275
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
結核病之藥物治療過程中常發生肝毒性之不良反應,而誘發肝毒性的因素除了與第一線抗結核藥物有關外,是否有其他潛在的因子可能影響抗結核藥物產生肝毒性,目前尚未有一致的定論。本研究目的在於探討病人本身疾病是否為影響發生肝毒性的相關因子。
本研究採回溯性病歷回顧自2007年1 月1日至2007年12月31日止為期一年,於南部某區域教學醫院門診或住院被首次診斷感染結核菌並接受抗結核藥物治療之病人,記錄其基本資料、疾病史、社交史、肝功能生化檢驗值等各項資料,並分析發生肝毒性的案例與其相關疾病因子是否具關聯性。
研究結果顯示,符合條件病人共228人,肝毒性發生率為61.0%(139人),高血壓與肝毒性的發生有顯著性相關(p=0.027)。本研究發現發生肝毒性時程主要集中在服藥後第一個月發生。
因此針對在服藥後第一個月發生肝毒性與否和病人的疾病因子加以分析:發現高血壓(p=0.008)、糖尿病(p=0.040)與消化性潰瘍(p=0.021)在第1個月就發生肝毒性有顯著性相關。
本研究顯示病人服用抗結核藥物發生肝毒性與病人高血壓疾病因子有顯著性相關。若以肝毒性是否在第一個月發生,則和高血壓或糖尿病或消化性潰瘍的病人有顯著性相關。因此建議在首次服用抗結核藥物時,須密切注意患有高血壓或糖尿病或消化性潰瘍的病人在第一個月產生肝毒性的情形。

Hepatotoxicity is an adverse reaction commonly observed during antituberculosis drug treatment. It is well known that the use of first-line antituberculosis drugs can induce hepatotoxicity; however, other potential factors for antituberculosis drug-induced hepatotoxicity have not yet come to a consistent conclusion. The study aimed to assess the role of comorbidity as a risk factor for the development of hepatotoxicity in patients with active tuberculosis receiving antituberculosis drug treatment.
This is an one-year retrospective study from January 1, 2007 to December 31, 2007 reviewing the medical charts of outpatients and inpatients with newly diagnosed tuberculosis and received treatment of antituberculosis drugs in a regional teaching hospital. The patient’s basic information, disease history, social history and liver function test results were recorded and analyzed for the correlation between the occurrence of hepatotoxicity and related underlying disease factors in these patients.
The results of the study have shown that a total of 228 patients met the study criteria and that the incidence of hepatotoxicity in these patients is 61.0% (139 patients). Hypertension (p=0.027) is found to be significantly associated with the occurrence of hepatotoxicity. This study demonstrated that hepatotoxicity occurred mainly within the first month of antituberculosis drug treatment. When the correlation of hepatotoxicity developed in the first month of antituberculosis drug treatment and the disease factors of patients were evaluated, it was observed that hypertension (p=0.008), diabetes (p=0.040) and peptic ulcers (p=0.021) were significantly correlated with development of hepatotoxicity in the first month of antituberculosis drug treatment.
The study has shown that development of hepatotoxicity is significantly associated in patients with hypertension, diabetes or peptic ulcer, within the first month of antituberculosis drug treatment.
It is therefore recommended that in the treatment-naive patients with underlying diseases such as hypertension, diabetes or peptic ulcer should be closely monitored for development of hepatotoxicity particularly during the first month of drug therapy.


目錄 i
表目錄 v
圖目錄 vii
誌謝 viii
中文摘要 ix
ABSTRACT xi
第一章 緒論 1
第二章 文獻探討 3
第一節 結核病流行病學 3
一、全球結核病流行趨勢 3
二、台灣結核病流行趨勢 4
第二節 結核病的特性與治療原則 6
一、特性 6
二、結核病的治療原則 6
第三節 藥物引起的肝毒性 9
一、肝毒性的定義與致病機轉 9
二、肝毒性的分類 11
第四節 抗結核藥物引起的肝毒性 13
一、第一線抗結核藥物致肝毒性之各論 13
第五節 影響抗結核藥物致肝毒性之危險因子 22
一、年齡(age) 22
二、性別(sex) 22
三、慢性病毒性肝炎感染(chronic viral hepatitis infection) 23
四、HIV感染(HIV infection) 24
五、共病(comorbidity) 25
六、白蛋白過低(hypoalbuminemia) 25
七、飲酒(alcohol consumption) 26
八、藥物乙醯化表現型(acetylator phenotype) 26
第三章 研究目的 28
第四章 研究方法 29
第一節 研究設計 29
第二節 研究對象 31
一、納入條件 31
二、排除條件 31
第三節 資料收集 33
一、病人基本資料 33
二、疾病史 33
三、社交史 34
四、用藥紀錄 34
五、肝功能生化檢驗值 34
六、其他生化檢驗值 35
第四節 資料統計與分析 36
第五節 肝毒性判定與評估標準 37
一、藥物引起肝毒性的判定標準 37
二、藥物引起肝毒性的評估標準 38
第五章 研究結果 39
第一節 研究對象基本資料分析 39
一、研究對象之納入情形 39
二、病人結核病相關診斷與肝毒性發生分布分析 42
第二節 肝毒性發生類型與發生率分析 43
第三節 發生肝毒性之危險因子分析 45
一、發生肝毒性與疾病因子分析 45
二、肝毒性發生時程與疾病因子分析 47
三、發生肝毒性之年齡層分析 49
第四節 病人共病數與發生肝毒性之關聯性 51
第六章 討論 53
第一節 樣本篩選 53
第二節 肝毒性的發生率 54
第三節 肝毒性發生與疾病因子關聯性 56
第四節 肝毒性發生與共病 57
第五節 肝毒性發生與年齡 58
第六節 研究限制 59
第七章 結論 60
第八章 參考文獻 62
附錄 70
附錄一 結核菌感染病人資料收集表 70
附錄二 人體試驗委員會同意臨床試驗證明書 72

1. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments: Rationale for monitoring liver status. Drug Saf. 1996;15(6):394-405.
2.World Health Organization. Treatment of Tuberculosis: guidelines for national programmes.3nd ed. Geneva: WHO Global Tuberculosis Programme. 2003.
3.Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. . Lancet 1997;350:624-629.
4.Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220-226.
5.American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Morbidity Mortality Weekly Rep (MMWR). 2003;52(RR-11):1-77.
6.行政院衛生署疾病管制局:結核病診治指引。2008;http://www.cdc.gov.tw/ct.asp?xItem=5710&ctNode=1540&mp=5230.
7.Small PM, Fujiwara PI. Management of Tuberculosis in the United States. N Engl J Med. 2001;345(3):189-200.
8.Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11(6):699-707.
9.American Thoracic Society. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med. 2006;174:935-952.
10.Fernández -Villar A, Sopena B, Fernández -Villar J, Vázquez-Gallardo, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499-1505.
11.Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, Salkeen S. Hepatotoxicity with Antituberculosis Drugs: The risk factors. Pak J Med Sci. 2007;23(1):33-38.
12.Nathwani R, Kaplowitz N. Drug Hepatotoxicity. Clin Liver Dis. 2006;10 207-217.
13.Tûrktas H, Ûnsal M, Tûlek N, Õrûc O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tubercule Lung Dis. 1994;75:58-60.
14.Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677-686.
15.Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003; 362:887-899.
16.Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med. 2005;11:189-194.
17.Potter B, Rindfleisch K, Kraus CK. Management of active tuberculosis. Am Fam Physician. 2005;72:2225-2232.
18.Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med. 2002;347(23):1860-1866.
19.World Health Organization. Tuberculosis Facts. 2006; http://www.who.int/tb/publications/2006/tb_factsheet_2006_1_en.pdf.
20.Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001;344(17):1294-1303.
21.World Health Organization. Global tuberculosis control-surveillance, planning, financing. 2006; http://www.who.int/tb/publications/global_report/en/index.html.
22.World Health Organization. Tuberculosis. 2008; http://www.who.int/mediacentre/factsheets/fs104/zh/index.html.
23.行政院衛生署疾病管制局:結核病統計年報。2009;http://www.cdc.gov.tw/lp.asp?ctNode=1525&CtUnit=830&BaseDSD=7&mp=230.
24.行政院衛生署疾病管制局;結核病。2009; http://www.cdc.gov.tw/sp.asp?xdurl=disease/disease_content.asp&id=777&mp=1&ctnode=1498#1.
25.Holt CD, Arriola E. Chapter 30: Adverse Effects of Drugs on the Liver. In: Koda-Kimble MA, Young LY, KradjanWA, Guglielmo BJ, Alldredge BA, Corelli RL, eds. Applied Therapeutics. 8 ed: LippincottWilliams &Wilkins; 2004:1-25.
26.Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;333(17):1118- 1127.
27.Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10(2): 207-217.
28.Navarro VJ, Senior JR. Current concepts: Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739.
29.Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474-485.
30.Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced injury in the United States. Liver Transpl. 2004;10:1018-1023.
31.Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61:135-143.
32.Benichou C(for the CIOMS). Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.
33.Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2:S44.
34.Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res. 2005;51(4):353-358.
35.Ormerod LP. Hepatotoxicity of antituberculosis drugs. Thorax. 1996;51:111- 113.
36.Richard Z. Adverse Effects of Anti-tuberculosis Chemotherapy, in European Respiratory Disease. 2006.
37.Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity.
J Gastroenterol Hepatol. 2005;20(11):1745-1752.
38.Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51(2):132-136.
39.Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004;38(6):1074-1079.
40.Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166(7):916-919.
41.Teleman MD, Chee CBE, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis. 2002;6(8):699-705.
42.Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-1477.
43.Ungo J R, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanes AP, et al. Antituberculosis drug-induced hepatotoxicity:The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1871-1876.
44.陳怡珊, 謝維清. 藥物引發之肝毒性-案例分析. 藥物安全簡訊. 2007;20:20-28.
45.陳映容, 陳燕惠. 抗結核藥物之藥物不良反應通報現況. 藥物安全簡訊. 2005;10:19-28.
46.Black M, Mitchell J, Zimmerman H, Ishak K, Epler G. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975; 69:289-302.
47.Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics. 2008;9(3):311-321.
48.Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005;45:177-202.
49.Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924-930.
50.Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62(6):423-429.
51.Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis. 2002;22(2):157-167.
52.Kopanoff DE, Snider D, Caras G. Isoniazid related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1979;117:991-1001.
53.Kays MB. Tuberculosis. Applied Therapeutics. 8 ed: Lippincott Williams & Wilkins; 2004:1-24.
54.Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123:1649-1658.
55.Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, et al. Isoniazid- and rifampicin-induced oxidative hepatic injury- protection by N-acetylcysteine. Hum Exp Toxicol. 2000;19:517-522.
56.Reddy KR, Schiff ER. Hepatotoxicity of amtimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin North Am. 1995;24:923-936.
57.Walubo A, Smith P, Folb PI. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. Meth Find Exp Clin Pharmacol. 1998;20:649-655.
58.Cascio A, Scarlata F, Giordano S, Antinori S, Colomba C, Titone L. Treatment of human brucellosis with rifampin plus minocycline. J Chemother. 2003;15:248-252.
59.Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ''null'' mutation. J Gastroenterol Hepatol. 2001;16:1033-1037.
60.U.S. Public Health Service. Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. Am Rev Respir Dis. 1969;59:13.
61.Centers for Disease Control and Prevention, American Thoracic Society. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States. Morbidity Mortality Weekly Rep (MMWR). 2001;50:733-735.
62.Knobel B, Buyanowsky G, Dan M, Zaidel L. Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol. 1997;24:264-266.
63.Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005;26:462-464.
64.Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002;167:131-136.
65.Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis. 1997;24:1264-1265.
66.Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of Pyrazinamide. Am J Respir Crit Care Med. 2008;177:1391-1396.
67.Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol. Br Med J (Clin Res Ed). 1986 March 29:292:866.
68.Gangadharam PRJ. Isoniazid, rifampin, and hepatotoxicity. Am Rev Respir Dis. 1986;133:963-965.
69.Lees AW, Asgher B, Hashem MA, Sinha BN. Jaundice after rifampicin. Br J Dis Chest. 1970;64:90-95.
70.Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991; 99:465-471.
71.Tripathy SP. Controlled clinical trial of a 3-month and two 5-month regimens in pulmonary tuberculosis. Second Madras short-course study. Bull Int Union Tuberc. 1983;58:97-100.
72.McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH. Twiceweekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. Am J Respir Crit Care Med 2000;162:989-993.
73.Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons. Chest. 2005;127:1296-1303.
74.McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003;123:102-106.
75.Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: amulticenter clinical trial. Ann Intern Med. 2002;137:640-647.
76.Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003;167:824-827.
77.Van Hest R, Baars H, Kik S, Van Gerven P, Trompenaars MC, Kalisvaart N, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39:488-496.
78.Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA. 2002;288:165-166.
79.Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Deggott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology. 1995;21:929-932.
80.Harding SM, Bailey WC. Chemotherapy of tuberculosis. In: D S, ed. Tuberculosis. Vol 3rd. New York: Springer-Verlag; 1994:69-88.
81.O''Brien RJ. Hepatoxic reaction to antituberculous drugs: adjustments to therapeutic regimen. JAMA. 1991;265:3323.
82.Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994;105:408-411.
83.Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic. JAMA. 1999;281(11):1014-1018.
84.LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168(4):443-447.
85.羅敏:結核病人使用抗結核藥物所致肝毒性之回溯性分析研究。國立台灣大學,碩士論文,1999。
86.Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis Drug-Induced hepatitis. Hepatology 2002;35:883-889.
87.Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996;77:37-42.
88.Schaberg T. The dark side of antituberculosis therapy: Adverse events involving liver function. Eur Respir J. 1995;8:1247-1249.
89.蕭斐元:預測抗結核藥物治療期間肝毒性之評分系統的建立。台北醫學大學,碩士論文,2003。
90.Hwang SJ, Wu JC, Lee CN, Yen F, Lu C, Lin T, et al. Drug-induced liver disease: a prospective clinical study of isoniazid-rifampicin-pyrazinamide induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87-91.
91.Franks A, Binkin N, Snider D, Rokaw W, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104:151- 155.
92.LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis. 2005;9:501-506.
93.Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116-123.
94.Devoto FM, Gonzalez C, Iannantuono R, Serra HA, Gonzalez CD, Saenz C. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam. 1997;47(4):197-202.
95.Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6(11):995-1000.
96.Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98:502-504.
97. Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters E, Mosteiro M,
et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis. 2003;36(3):293-298.
98.陳映蓉:抗結核藥物致肝毒性之前瞻性分析研究。國立台灣大學,碩士論文,2002。
99.楊敏慧:台灣地區結核病流行趨勢與前瞻性分析抗結核藥物導致肝損傷之相關性研究。中國醫藥大學,碩士論文,2007。
100.El-Sadr WM, Perlman DC, Matts JP, Nelson E, Cohn D, Salomon N, et al. Evaluation of an intensive intermittent-induction regimen and duration of shortcourse treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis. 1998;26:1148-1158.
101.Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026-2030.
102.高郁雯:預測抗結核藥物治療期間肝毒性之評分系統的驗證。臺北醫學大學,碩士論文,2006。
103.Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle. 1984;65:211-227.
104.Reidenberg MM, Drayer DE. Drug metabolism and active drug metabolites in renal failure. J Dialysis. 1977;1:313-318.
105.Iselius L , Evans DAP. Formal genetics of isoniazid metabolism in man. Clin Pharmacokinetics. 1983;8:541-544.
106.Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000;4(3):256-261.
107.National Center for Health Statistics (NCHS). International Classification of Diseases, Ninth Revision (ICD-9). http://icd9cm.chrisendres.com/index.php?action=child&recordid=97.
108.Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberst EA, et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔